263 related articles for article (PubMed ID: 29884162)
1. Nivolumab-induced thyroid dysfunction lacking antithyroid antibody is frequently evoked in Japanese patients with malignant melanoma.
Yano S; Ashida K; Nagata H; Ohe K; Wada N; Takeichi Y; Hanada Y; Ibayashi Y; Wang L; Sakamoto S; Sakamoto R; Uchi H; Shiratsuchi M; Furue M; Nomura M; Ogawa Y
BMC Endocr Disord; 2018 Jun; 18(1):36. PubMed ID: 29884162
[TBL] [Abstract][Full Text] [Related]
2. Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab.
de Filette J; Jansen Y; Schreuer M; Everaert H; Velkeniers B; Neyns B; Bravenboer B
J Clin Endocrinol Metab; 2016 Nov; 101(11):4431-4439. PubMed ID: 27571185
[TBL] [Abstract][Full Text] [Related]
3. Changes in TgAb and TPOAb titers are greater in thyrotoxicosis than isolated hypothyroidism induced by PD-1 blockade.
Yamagami A; Iwama S; Kobayashi T; Zhou X; Yasuda Y; Okuji T; Ito M; Izuchi T; Ando M; Onoue T; Miyata T; Sugiyama M; Hagiwara D; Suga H; Banno R; Arima H
Endocr J; 2024 Apr; ():. PubMed ID: 38599854
[TBL] [Abstract][Full Text] [Related]
4. A real-world study on the safety profile of extended-interval dosing of immune checkpoint inhibitors for melanoma: a single-center analysis in Japan.
Ito T; Kaku-Ito Y; Ohno F; Nakahara T
Front Med (Lausanne); 2023; 10():1293397. PubMed ID: 38143437
[TBL] [Abstract][Full Text] [Related]
5. Thyroid dysfunction induced by anti-PD-1 therapy is associated with a better progression-free survival in patients with advanced carcinoma.
Lu Y; Li Q; Xu L; Zheng Y; Wang Y; Liu Y; Zhang R; Liao L; Dong J
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16501-16510. PubMed ID: 37715029
[TBL] [Abstract][Full Text] [Related]
6. Improved overall survival in patients developing endocrine toxicity during treatment with nivolumab for advanced non-small cell lung cancer in a prospective study.
Albertelli M; Rossi G; Nazzari E; Genova C; Biello F; Rijavec E; Dal Bello MG; Patti L; Tagliamento M; Barletta G; Morabito P; Boschetti M; Dotto A; Campana D; Ferone D; Grossi F
J Endocrinol Invest; 2024 Apr; ():. PubMed ID: 38683497
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Associated Factors for Thyroid Dysfunction Among Patients On Targeted Therapy for Cancers: A Single-Center Study from Thailand.
Chawalitmongkol K; Maneenil K; Thungthong P; Deerochanawong C
J ASEAN Fed Endocr Soc; 2023; 38(2):77-85. PubMed ID: 38045662
[TBL] [Abstract][Full Text] [Related]
8. Factors associated with immune-related thyroid dysfunction induced by PD-1/PD-L1 inhibitors in cancer patients: an observational study.
Wei XC; Guo YY; Zhang Y; Bu YS; Zhang FY
J Chemother; 2024 Jan; ():1-8. PubMed ID: 38240051
[TBL] [Abstract][Full Text] [Related]
9. Steroid treatment in the management of destructive thyrotoxicosis induced by PD1 blockade.
Brancatella A; Pierotti L; Viola N; Lupi I; Montanelli L; Cremolini C; Piaggi P; Chella A; Antonuzzo A; Sgrò D; Antonangeli L; Sardella C; Brogioni S; Marcocci C; Santini F; Latrofa F
Eur Thyroid J; 2022 Aug; 11(4):. PubMed ID: 35622442
[TBL] [Abstract][Full Text] [Related]
10. Amplification and attenuation of lung metastases depending on glucocorticoid dosage implicating long-acting activated memory cells induced by nivolumab against malignant melanoma.
Katagiri K; Shiga K; Saito D; Oikawa SI; Ikeda A; Tsuchida K; Miyaguchi J
Clin Case Rep; 2019 Sep; 7(9):1709-1713. PubMed ID: 31534732
[TBL] [Abstract][Full Text] [Related]
11. Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab.
Toi Y; Sugawara S; Kawashima Y; Aiba T; Kawana S; Saito R; Tsurumi K; Suzuki K; Shimizu H; Sugisaka J; Ono H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y
Oncologist; 2018 Nov; 23(11):1358-1365. PubMed ID: 29934411
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
[TBL] [Abstract][Full Text] [Related]
13. Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab.
Scott SC; Pennell NA
J Thorac Oncol; 2018 Nov; 13(11):1771-1775. PubMed ID: 29935305
[TBL] [Abstract][Full Text] [Related]
14. Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.
Clotman K; Janssens K; Specenier P; Weets I; De Block CEM
J Clin Endocrinol Metab; 2018 Sep; 103(9):3144-3154. PubMed ID: 29955867
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced thyroid dysfunction in patients with lung cancer.
Ramos-Levi AM; Rogado J; Sanchez-Torres JM; Colomer R; Marazuela M
Endocrinol Diabetes Nutr (Engl Ed); 2019 Jan; 66(1):26-34. PubMed ID: 29910159
[TBL] [Abstract][Full Text] [Related]
16. Patterns of disease control and survival in patients with melanoma brain metastases undergoing immune-checkpoint blockade.
Milsch L; Gesierich A; Kreft S; Livingstone E; Zimmer L; Goebeler M; Schadendorf D; Schilling B
Eur J Cancer; 2018 Aug; 99():58-65. PubMed ID: 29906735
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of ipilimumab and nivolumab induced thyroid storm in a patient with Hashimoto's disease and diabetes mellitus: a case report.
Yonezaki K; Kobayashi T; Imachi H; Yoshimoto T; Kikuchi F; Fukunaga K; Sato S; Ibata T; Yamaji N; Lyu J; Dong T; Murao K
J Med Case Rep; 2018 Jun; 12(1):171. PubMed ID: 29914537
[TBL] [Abstract][Full Text] [Related]
18. Fulminant onset of insulin-dependent diabetes with positive anti-GAD antibody titers during treatment with nivolumab in a patient with NSCLC.
Matsuura N; Koh G; Konishi C; Minamino S; Takahara Y; Harada H; Kodama K; Emoto M
Cancer Immunol Immunother; 2018 Sep; 67(9):1417-1424. PubMed ID: 29995236
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.
Afzal MZ; Mercado RR; Shirai K
J Immunother Cancer; 2018 Jul; 6(1):64. PubMed ID: 29966520
[TBL] [Abstract][Full Text] [Related]
20. Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma.
Quispel-Janssen J; van der Noort V; de Vries JF; Zimmerman M; Lalezari F; Thunnissen E; Monkhorst K; Schouten R; Schunselaar L; Disselhorst M; Klomp H; Hartemink K; Burgers S; Buikhuisen W; Baas P
J Thorac Oncol; 2018 Oct; 13(10):1569-1576. PubMed ID: 29908324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
